These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 20156111)

  • 1. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.
    Santos R; Lefevre S; Sliwa D; Seguin A; Camadro JM; Lesuisse E
    Antioxid Redox Signal; 2010 Sep; 13(5):651-90. PubMed ID: 20156111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Missense mutations linked to friedreich ataxia have different but synergistic effects on mitochondrial frataxin isoforms.
    Li H; Gakh O; Smith DY; Ranatunga WK; Isaya G
    J Biol Chem; 2013 Feb; 288(6):4116-27. PubMed ID: 23269675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Friedreich Ataxia: From the Eye of a Molecular Biologist.
    Muthuswamy S; Agarwal S
    Neurologist; 2015 Sep; 20(3):51-5. PubMed ID: 26375377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.
    Igoillo-Esteve M; Oliveira AF; Cosentino C; Fantuzzi F; Demarez C; Toivonen S; Hu A; Chintawar S; Lopes M; Pachera N; Cai Y; Abdulkarim B; Rai M; Marselli L; Marchetti P; Tariq M; Jonas JC; Boscolo M; Pandolfo M; Eizirik DL; Cnop M
    JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31877117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Mechanisms and Therapeutics for the GAA·TTC Expansion Disease Friedreich Ataxia.
    Gottesfeld JM
    Neurotherapeutics; 2019 Oct; 16(4):1032-1049. PubMed ID: 31317428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodegeneration in Friedreich's ataxia: from defective frataxin to oxidative stress.
    Gomes CM; Santos R
    Oxid Med Cell Longev; 2013; 2013():487534. PubMed ID: 23936609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron metabolism and mitochondrial abnormalities in Friedreich ataxia.
    Pandolfo M
    Blood Cells Mol Dis; 2002; 29(3):536-47; discussion 548-52. PubMed ID: 12547248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiogical and therapeutic progress in Friedreich ataxia.
    Puccio H; Anheim M; Tranchant C
    Rev Neurol (Paris); 2014 May; 170(5):355-65. PubMed ID: 24792433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice harboring the FXN I151F pathological point mutation present decreased frataxin levels, a Friedreich ataxia-like phenotype, and mitochondrial alterations.
    Medina-Carbonero M; Sanz-Alcázar A; Britti E; Delaspre F; Cabiscol E; Ros J; Tamarit J
    Cell Mol Life Sci; 2022 Jan; 79(2):74. PubMed ID: 35038030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The displacement of frataxin from the mitochondrial cristae correlates with abnormal respiratory supercomplexes formation and bioenergetic defects in cells of Friedreich ataxia patients.
    Doni D; Rigoni G; Palumbo E; Baschiera E; Peruzzo R; De Rosa E; Caicci F; Passerini L; Bettio D; Russo A; Szabò I; Soriano ME; Salviati L; Costantini P
    FASEB J; 2021 Mar; 35(3):e21362. PubMed ID: 33629768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia.
    Galea CA; Huq A; Lockhart PJ; Tai G; Corben LA; Yiu EM; Gurrin LC; Lynch DR; Gelbard S; Durr A; Pousset F; Parkinson M; Labrum R; Giunti P; Perlman SL; Delatycki MB; Evans-Galea MV
    Ann Neurol; 2016 Mar; 79(3):485-95. PubMed ID: 26704351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel deletion-insertion mutation identified in exon 3 of FXN in two siblings with a severe Friedreich ataxia phenotype.
    Evans-Galea MV; Corben LA; Hasell J; Galea CA; Fahey MC; du Sart D; Delatycki MB
    Neurogenetics; 2011 Nov; 12(4):307-13. PubMed ID: 21830088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frataxin gene point mutations in Italian Friedreich ataxia patients.
    Gellera C; Castellotti B; Mariotti C; Mineri R; Seveso V; Didonato S; Taroni F
    Neurogenetics; 2007 Nov; 8(4):289-99. PubMed ID: 17703324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches.
    Schmucker S; Puccio H
    Hum Mol Genet; 2010 Apr; 19(R1):R103-10. PubMed ID: 20413654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia.
    Rodríguez-Pascau L; Britti E; Calap-Quintana P; Dong YN; Vergara C; Delaspre F; Medina-Carbonero M; Tamarit J; Pallardó FV; Gonzalez-Cabo P; Ros J; Lynch DR; Martinell M; Pizcueta P
    Neurobiol Dis; 2021 Jan; 148():105162. PubMed ID: 33171227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.
    Marmolino D; Acquaviva F
    Cerebellum; 2009 Sep; 8(3):245-59. PubMed ID: 19165552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Friedreich's ataxia: past, present and future.
    Marmolino D
    Brain Res Rev; 2011 Jun; 67(1-2):311-30. PubMed ID: 21550666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterising the neuropathology and neurobehavioural phenotype in Friedreich ataxia: a systematic review.
    Corben LA; Georgiou-Karistianis N; Bradshaw JL; Evans-Galea MV; Churchyard AJ; Delatycki MB
    Adv Exp Med Biol; 2012; 769():169-84. PubMed ID: 23560311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicellular models of Friedreich ataxia.
    Puccio H
    J Neurol; 2009 Mar; 256 Suppl 1():18-24. PubMed ID: 19283346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the gene in Friedreich ataxia.
    Hebert MD
    Biochimie; 2008 Aug; 90(8):1131-9. PubMed ID: 18206656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.